Loading...

Targeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins

Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic β-cells or a reduction in β-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on β-cell physiology as we...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Salehi, Marzieh, Aulinger, Benedikt A., D'Alessio, David A.
Format: Artigo
Sprog:Inglês
Udgivet: The Endocrine Society 2008
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2528856/
https://ncbi.nlm.nih.gov/pubmed/18292465
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/er.2007-0031
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!